Journal: Scientific reports
This study conducted a Bayesian network meta-analysis to indirectly compare overall survival (OS) and progression-free survival (PFS) of the triplet therapy darolutamide (DAR) plus docetaxel (DOC) and androgen deprivation therapy (ADT) against other approved treatments for metastatic hormone-sensitive prostate cancer (mHSPC) in China.
Comparator regimens included:
- Enzalutamide + ADT
- Apalutamide + ADT
- Docetaxel + ADT
- Abiraterone + ADT
- Rezvilutamide + ADT
The analysis showed that DAR+DOC+ADT consistently favored improved OS and PFS compared to these treatments, with statistically significant hazard ratios favoring DAR+DOC+ADT versus DOC+ADT, ADT alone, and nonsteroidal antiandrogen plus ADT in both the intention-to-treat and high-volume populations.
The only exception was abiraterone plus ADT, which did not show a statistically significant difference in OS under random effects analysis.
Limitations include variability in PFS definitions across trials.
Overall, results support DAR+DOC+ADT as an effective frontline therapy for mHSPC, especially in the Chinese context where rezvilutamide is also available.